Molluscum contagiosum
Conditions
Interventions
Treatment Group: SB206 is applied once daily for 12 weeks.
Control Group: Vehicle is applied once daily for 12 weeks.
Sponsors
Kaneko Yoshiyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Japanese patients with molluscum contagiosum aged 2 years or older and in good general health; - Patients who are able to understand and follow study instructions or who have support from the parent or legal guardian; - Patients who have a documented informed consent from voluntary signed by subject or a representative (parent or legal guardian) who received full explanations regarding the objectives and details of the study and the study drug.
Exclusion criteria
Exclusion criteria: - Patients who have molluscum contagiosum only in periocular area; - Patients who have received any treatment for molluscum contagiosum during the 14 days prior to Baseline; - Patients who are suspected to be immunosuppressed or have immunodeficiency disorder, or are on immunosuppressive treatment; - Patients who have history or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects with complete clearance of all treatable MC at Week 12. | — |
Contacts
Public ContactClinical Trials Information Desk
Sato Pharmaceutical Co., Ltd.
Outcome results
None listed